News
Caplacizumab improves outcomes in aTTP
ATLANTA—Caplacizumab can improve outcomes in patients with acquired thrombotic thrombocytopenic purpura (aTTP), according to research presented at...
News
Chemo-free combo should be option for rel/ref CLL, doc says
ATLANTA—The combination of venetoclax and rituximab (VR) should be a standard treatment option for adults with relapsed/refractory chronic...
News
Edoxaban noninferior to dalteparin for VTE in cancer
ATLANTA—Edoxaban is noninferior to dalteparin for the treatment of cancer-associated venous thromboembolism (VTE), a phase 3 study suggests. In...
News
Combo should be standard in MM, doc says
ATLANTA—Study results “strongly support” a new standard of care for transplant-ineligible patients with newly diagnosed multiple myeloma (MM),...
News
Emicizumab reduces bleeds in kids with hemophilia A and inhibitors
ATLANTA—Updated results from the HAVEN 2 trial have shown that emicizumab prophylaxis can reduce bleeds in children with hemophilia A and factor...
News
Team discovers oncogenic driver of T-ALL
Preclinical research suggests the TOX protein is an oncogenic driver of T-cell acute lymphoblastic leukemia (T-ALL). Results indicate that TOX...
News
FDA warns about risk of death with pembrolizumab in MM
The US Food and Drug Administration (FDA) has issued a statement warning about an increased risk of death associated with an unapproved use of...
News
Methotrexate could treat myeloproliferative neoplasms
Methotrexate (MTX) may be a feasible treatment option for myeloproliferative neoplasms (MPNs), according to preclinical research published in...
News
Drug receives orphan designation for ocular GVHD
The US Food and Drug Administration (FDA) has granted orphan drug designation to OCU300 (brimonidine tartrate) for the treatment of ocular graft-...
News
KRD appears more active, less safe than KCD in newly diagnosed MM
MADRID—New research suggests one triplet regimen may be more active but also more toxic than another in patients with newly diagnosed multiple...
News
High ORR with sequential regimen in CLL
LUGANO, SWITZERLAND—A sequential treatment regimen can produce a high overall response rate (ORR) in patients with treatment-naïve (TN) or...
News
Combo may be option for elderly patients with untreated AML
MADRID—The combination of venetoclax and low-dose cytarabine (VEN+LDAC) appears to be a feasible treatment option for elderly patients with...
News
GAD-M produces high ORR in treatment-naïve ENKTL
LUGANO, SWITZERLAND—A 4-drug regimen has demonstrated efficacy in a phase 2 trial of patients with treatment-naïve extranodal natural killer/T-...
News
CTL019 produces responses in rel/ref DLBCL
The chimeric antigen receptor (CAR) T-cell therapy CTL019 produced a high response rate in a phase 2 trial of adults with relapsed/refractory...
News
Combo demonstrates activity in CLL/SLL and FL
LUGANO, SWITZERLAND—Results of a phase 1 study suggest a 2-drug combination may be safe and effective in patients with chronic lymphocytic...